InvestorsHub Logo
Followers 19
Posts 4540
Boards Moderated 0
Alias Born 04/12/2017

Re: Investor2014 post# 431990

Thursday, 09/21/2023 9:42:06 AM

Thursday, September 21, 2023 9:42:06 AM

Post# of 459928
Yea because making revenue, which we can use to conduct the confirmatory trial, is not saving money?

vs running the trial our of the pocket of the investors??

A company that achieves AA must subsequently in any case obtain traditional approval to continue marketing their treatment/drug. There is no free lunch, but an intention to make a potentially beneficial drug available to early..



Ad-hominem lol

Did you miss the part where I highlighted, we do not have a traditional P3??

You said this:


The above quote could be part of the explanation for why you are not a Biotech Expert.
Biotech/pharma companies with complete and positive P3 data would file for traditional approval and avoid the additional post marketing confirmatory trial requirement thereby saving time and money. You see the idea is that a P3 is the confirmatory trial.



From my post:

Is not a traditional P3 trial. With our trials design being a P2b/P3 AA is a no brainer.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News